Why the study?
Does methotrexate improve response rate in patients with advanced bladder cancer?
Does methotrexate improve response rate in patients with advanced bladder cancer?
Methotrexate, particularly at 100 mg IV every 2 weeks, provides a 56% response rate and is well tolerated in patients with advanced bladder cancer with normal renal function.
Answers are grounded in this paper and cite their sources.
May support methotrexate in select advanced bladder cancer cases; hypothesis-generating and should not yet change practice.
61 patients with advanced bladder cancer were treated with methotrexate. 3 different regimes were used, 2 given on an out-patient and 1 on an in-patient basis. A response rate of 56% was found in patients who received 100 mg of methotrexate intravenously every 2 weeks as an out-patient. Provided that renal function is checked before therapy and is normal, then methotrexate can be used safely; it being well tolerated and having few serious side-effects.
No takes yet. Share an insight, caveat, or question.
Turner et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: